🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Welcome to the Providence Therapeutics Twitter page! Follow us for company updates and information about our #vaccines in development for #cancer and #InfectiousDiseases. Visit our website for more info: bit.ly/40qHZgo

Our CFO, Judyanna Yu, CPA, CA, and BD Manager, Jordan Schwartz, Ph.D., are attending the @bloomburton #Healthcare Investor Conference at the Metro #Toronto Convention Centre from April 25-26. Please reach out if you’d like to connect with us there! #BBHIC2023

Our CFO, Judyanna Yu, CPA, CA, and BD Manager, Jordan Schwartz, Ph.D., are attending Mintz Early-Stage #LifeSciences Companies & Investors Networking Event in #Toronto on Monday, April 24. They look forward to meeting with investors at the event!

Happy National #Immunization Awareness Week! We're proud to support this campaign led by Immunize Canada & Cdn Public Health Assoc. highlighting the importance of routine immunizations to protect the Canadian population against vaccine-preventable diseases. #NIAW2023 #VaccinesWork #GetImmunized

Our CFO, Judyanna Yu, CPA, CA, and President & CTO, Robert Georgantas III, Ph.D., are attending Biotechnology Innovation Organization's BIO International Convention in Boston from June 5-8. Please reach out if you’d like to meet us there: bit.ly/41ZaCD0 #BIO2023

Our Business Development Manager, Jordan Schwartz, Ph.D., spoke yesterday at the MaRS Impact Health event. It was great to meet with and hear from others in the Canadian #healthcare innovation community! #MaRSImpactHealth

Our President & Chief Technology Officer, Robert Georgantas III, Ph.D., is participating in BioProcess Online upcoming panel to discuss the therapeutic #vaccine revolution and overcoming development and manufacturing challenges. Register for the panel here: bit.ly/3IqoQFj

A new paper in Scientific Reports, an open-access part of the Nature Portfolio, details the results of Providence's Phase 1 study of its mRNA-based COVID-19 vaccine candidate, the first clinical study to demonstrate encouraging data on Providence's mRNA platform: nature.com/articles/s4159…

Our Chief Financial Officer, Judyanna Yu, CPA, CA, and President & Chief Technology Officer, Robert Georgantas III, Ph.D., look forward to meeting fellow industry leaders at the Biotechnology Innovation Organization Convention. Reach out if you would like to meet us there: bit.ly/41ZaCD0 #BIO2023

We are thrilled to announce our partnership with the University Health Network to develop mRNA-based vaccines and therapeutics for those living with difficult-to-treat #cancers and #InfectiousDiseases. Learn more about our collaboration with the University Health Network here: bit.ly/43k8Mxk

Our Chief Financial Officer, Judyanna Yu, CPA, CA, and President & Chief Technology Officer, Robert Georgantas III, Ph.D., are enjoying connecting with industry leaders at the Biotechnology Innovation Organization Convention. Reach out if you would like to meet: bit.ly/41ZaCD0 #BIO2023

Our Chief Science Officer, Natalia Martin Orozco, Ph.D., will present at the Mexican Society of Immunology's 25th National Congress in Santiago de Querétaro, Mexico on Wednesday, June 7. Learn more here: bit.ly/426FKQb Sociedad Mexicana de Inmunología (SMI)

We're proud to be a gold sponsor of the Western Canada RNA Conference, RiboWest 2023, which brings together #RNA scientists from across #Canada and the northwestern United States. Our team will present on June 26 at 2:15 p.m. PT at University of Northern British Columbia (UNBC). Learn more here: fal.cn/3zlZK

Our Chief Medical Officer, Aleksandra Pastrak, M.D., Ph.D., and Senior Research Associate, Kirstin Olsen, will be presenting at the 3rd Annual #mRNA Based Therapeutics Summit in #Boston next Thursday and Friday. Learn more and register here: fal.cn/3A0VI

Our Chief Medical Officer, Aleksandra Pastrak, M.D., Ph.D., & Senior Research Associate, Kirstin Olsen, enjoyed presenting at this year’s #mRNA Based Therapeutics Summit in #Boston, where they had the opportunity to connect with others in the industry working on mRNA #research.

Our President & CTO, Robert Georgantas III, Ph.D., was featured in a Drug Discovery News article highlighting the advantages of mRNA-based vaccines and our pipeline of vaccines in development for aggressive #cancers and #InfectiousDiseases. Read more here: fal.cn/3AkJ2